Italia markets closed

T2 Biosystems, Inc. (0A57.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
0,4229+0,0180 (+4,45%)
Alla chiusura: 04:56PM GMT
Schermo intero
Chiusura precedente0,4049
Aperto0,4229
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,4229 - 0,4229
Intervallo di 52 settimane0,4229 - 0,4229
Volume1.000
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)0,18
Rapporto PE (ttm)N/D
EPS (ttm)-0,3050
Prossima data utili02 mar 2022 - 07 mar 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results

    LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2021. Recent Highlights (unaudited) Achieved full year 2021 total revenue of $27.7 million, including product revenue of $16.7 million, representing an increase of 53% and 43%, respectively compared to the prior yearAchieved fourth quarter tot

  • GlobeNewswire

    T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial

    LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initation of a U.S. clinical trial evaluating the performance of its T2Biothreat® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA). The T2Biothreat® Panel, which runs on T2 Biosystems’ T2Dx® Instrument, is a direct-from-blood test panel that provides results in 3-5 hours and simultaneously dete

  • GlobeNewswire

    T2 Biosystems Announces the Initiation of the T2Resistance® Panel Clinical Trial

    LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initiation of a U.S. multi-site clinical trial evaluating the performance of its T2Resistance® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA). The T2Resistance® Panel, which runs on T2 Biosystems’ T2Dx® Instrument, is a direct-from-blood test panel that detects 13 antibiotic resistance genes